2358 Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Virginia, USA.
2358 Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia, Virginia, USA.
Am Surg. 2021 Apr;87(4):568-575. doi: 10.1177/0003134820950685. Epub 2020 Oct 29.
Postoperative glycemic control improves cardiac surgery outcomes but insulin protocols are limited by complexity and inflexibility. We sought to evaluate the effect of implementing an electronic glycemic management system (eGMS) in conjunction with a cardiac surgery endocrinology consult service on glycemic control and outcomes after cardiac surgery.
All patients with a calculated preoperative risk of mortality who underwent cardiac surgery before and after implementation of an eGMS and an endocrinology consult service were identified. Glycemic control and surgical outcomes were compared using univariate analysis, and multivariate regression was used to model the risk-adjusted effects of the interventions on glycemic control, surgical outcomes, and resource utilization. The health care-related value added by the interventions was calculated by dividing risk-adjusted outcomes by total hospital costs.
A total of 2612 patients were identified, with 1263 patients in the preimplementation cohort and 1349 in the postimplementation cohort. Multivariate regression demonstrated fewer postoperative hyperglycemic events (odds ratio [OR] 0.8, 95% CI, 0.65-0.99) after protocol implementation without an increase in hypoglycemic events (OR 0.96, 95% CI, 0.71-1.3). Average day-weighted mean glucose decreased from 144 to 138 mg/dL ( < .001). The improved glycemic control correlated with a risk-adjusted decrease in composite morbidity or mortality (OR 0.61, 95% CI, 0.47-0.79). Although hospital costs increased after implementation, the protocol increased health care-related value by 38%.
Implementation of a protocol consisting of an eGMS paired with a cardiac surgery-specific endocrinology consult service was associated with improved glycemic control and reduced morbidity. Despite higher costs health care-related value increased as a result of eGMS implementation.
术后血糖控制可改善心脏手术结果,但胰岛素方案受到复杂性和灵活性的限制。我们评估了在心脏手术内分泌会诊服务的基础上实施电子血糖管理系统(eGMS)对心脏手术后血糖控制和结果的影响。
确定了所有术前死亡率计算风险较高并在实施 eGMS 和内分泌会诊服务前后接受心脏手术的患者。使用单变量分析比较血糖控制和手术结果,使用多变量回归对干预措施对血糖控制、手术结果和资源利用的风险调整效果进行建模。通过将风险调整后的结果除以总住院费用来计算干预措施的医疗相关附加值。
共确定了 2612 例患者,其中 1263 例在实施前队列中,1349 例在实施后队列中。多变量回归显示,方案实施后术后高血糖事件减少(优势比 [OR] 0.8,95%CI,0.65-0.99),而低血糖事件无增加(OR 0.96,95%CI,0.71-1.3)。平均日加权平均血糖从 144 降至 138 mg/dL(<0.001)。血糖控制的改善与复合发病率或死亡率的风险调整降低相关(OR 0.61,95%CI,0.47-0.79)。尽管实施后医院成本增加,但该方案增加了 38%的医疗相关附加值。
实施由 eGMS 与心脏手术特定内分泌会诊服务相结合的方案与改善血糖控制和降低发病率相关。尽管成本较高,但由于 eGMS 的实施,医疗相关附加值增加。